Company Analysis

Scinai Immunotherapeutics Ltd. (SCNI)

Nasdaq: SCNI · Biological Products, (No Diagnostic Substances) · Jerusalem, IL · filing with the SEC since 2014
Grade3.9
◀ Past 3.5● Present 3.8▶ Future 4.3
5 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Scinai Immunotherapeutics Ltd.’s names, not what it holds today.

Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
4
since 2001, to Dec 31, 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'14'16'17'19'20
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name2 counted
BIONDVAX PHARMACEUTICALS LTD. a former name
IL, as the owner printed on each patent
4 granted
3 published
BIONDVAX PHARMACEUTICALS LTD. a former name
named as the applicant on its applications, in IL
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 1, 201910,426,828Compositions of multimeric-multiepitope influenza polypeptides and their productionPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD.
May 31, 20169,353,159Multimeric multiepitope influenza vaccinesPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD.
Apr 5, 20169,303,070Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccinesPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD.
Jun 10, 20148,747,861Multimeric multiepitope influenza vaccinesPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jan 2, 20202020/0000910COMPOSITIONS OF MULTIMERIC-MULTIEPITOPE INFLUENZA POLYPEPTIDES AND THEIR PRODUCTIONPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD.
Jun 22, 20172017/0173142COMPOSITIONS OF MULTIMERIC-MULTIEPITOPE INFLUENZA POLYPEPTIDES AND THEIR PRODUCTIONPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD. · patent 10,426,828 granted from it
Sep 25, 20142014/0286982MULTIMERIC MULTIEPITOPE INFLUENZA VACCINESPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD. · patent 9,353,159 granted from it
Aug 14, 20142014/0227306MULTIMERIC MULTIEPITOPE POLYPEPTIDES IN IMPROVED SEASONAL AND PANDEMIC INFLUENZA VACCINESPharmaceuticalsBIONDVAX PHARMACEUTICALS LTD. · patent 9,303,070 granted from it

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SCNI · research, not advice